(PRWEB) July 2, 2005
SCIREX Corporation announced today that Robert R. Allen, M.D., has been appointed Executive Officer, Science and Medicine, Office of the President, Clinical Site Operations. In his new role as the CSO divisionÂs chief scientist he will be responsible for the scientific and medical oversight of studies conducted at SCIREXÂs clinical research sites, and will formulate and oversee the execution of the divisionÂs research and development strategy. Dr. Allen will be a member of SCIREXÂs Senior Management Committee, reporting directly to Chief Executive Officer Jim Utterback.
Dr. Allen joins SCIREX from AstraZeneca where most recently he was Executive Director, Discovery Medicine/Neuroscience, Global Research & Development. In this role he was responsible for the definition and implementation of translational neuroscience strategy and for building the Global Clinical Discovery Medicine Group in neuroscience. His prior positions at AstraZeneca included Vice President, Neuroscience/Disease Area Physician and Vice President, Pain and Anesthesia Therapy Area.
Dr. Allen received his B.A. in Biology from Boston College and his M.D. from Tufts University Medical School. He completed residencies in Internal Medicine at Faulkner Hospital in Boston and in Neurology at the University of Michigan in Ann Arbor, and served as Chief Resident, Internal Medicine at Faulkner Hospital. He holds professional memberships in the American Academy of Neurology, the American Pain Society, and the International Pain Society. He has been an invited lecturer on many occasions on topics including the treatment of neuropathic pain, chronic pain, and pain management. Additionally, he has been well published as author or co-author of many articles, abstracts, and book chapters on subjects related to his fields of expertise.
SCIREX Corporation is a leader in the delivery of Phase I-IV drug development services to the global pharmaceutical and biotechnology industries. SCIREXÂs clinical trial management capabilities include drug development planning, protocol design, submission services, regulatory affairs consulting, investigator and patient recruitment, data management, statistics, medical writing and offers an array of technology solutions including IVRS, EDC and SIMS(TM) (Study Information Management System). SCIREXÂs experience portfolio includes more than 1,000 clinical trials involving well over 100,000 patients, evaluating new treatments for pain and inflammation, neurological and psychiatric disorders, infectious diseases and gastrointestinal and cardiovascular indications. SCIREX is a wholly-owned subsidiary of Omnicom Group, Inc.
For more information contact Blythe Vito, SCIREX Corporate Marketing at (215) 907-1330 x1054, or visit http://www.scirex.com.